These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12699244)

  • 1. Residual activity of human porphobilinogen deaminase with R167Q or R167W mutations: an explanation for survival of homozygous and compound heterozygous acute intermittent porphyrics.
    Edixhoven-Bosdijk A; de Rooij FW; de Baar-Heesakkers E; Wilson JH
    Cell Mol Biol (Noisy-le-grand); 2002 Dec; 48(8):861-6. PubMed ID: 12699244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute intermittent porphyria--impact of mutations found in the hydroxymethylbilane synthase gene on biochemical and enzymatic protein properties.
    Ulbrichova D; Hrdinka M; Saudek V; Martasek P
    FEBS J; 2009 Apr; 276(7):2106-15. PubMed ID: 19292878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between biochemical findings, structural and enzymatic abnormalities in mutated HMBS identified in six Israeli families with acute intermittent porphyria.
    Ulbrichova D; Schneider-Yin X; Mamet R; Saudek V; Martasek P; Minder EI; Schoenfeld N
    Blood Cells Mol Dis; 2009; 42(2):167-73. PubMed ID: 19138865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria.
    Yasuda M; Gan L; Chen B; Yu C; Zhang J; Gama-Sosa MA; Pollak DD; Berger S; Phillips JD; Edelmann W; Desnick RJ
    Hum Mol Genet; 2019 Jun; 28(11):1755-1767. PubMed ID: 30615115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute intermittent porphyria: the in vitro expression of mutant hydroxymethylbilane synthase.
    Ong PM; Lanyon WG; Graham G; Hift RJ; Halkett J; Moore MR; Connor JM
    Mol Cell Probes; 1997 Aug; 11(4):293-6. PubMed ID: 9281416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The three-dimensional structures of mutants of porphobilinogen deaminase: toward an understanding of the structural basis of acute intermittent porphyria.
    Brownlie PD; Lambert R; Louie GV; Jordan PM; Blundell TL; Warren MJ; Cooper JB; Wood SP
    Protein Sci; 1994 Oct; 3(10):1644-50. PubMed ID: 7849582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular forms of porphobilinogen deaminase in acute intermittent porphyria. A study by Western immunoblotting.
    Nunn AV; Gardner LC; Cox TM
    Q J Med; 1987 Jul; 64(243):589-99. PubMed ID: 3671663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute intermittent porphyria: expression of mutant and wild-type porphobilinogen deaminase in COS-1 cells.
    Mustajoki S; Laine M; Lahtela M; Mustajoki P; Peltonen L; Kauppinen R
    Mol Med; 2000 Aug; 6(8):670-9. PubMed ID: 11055586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute intermittent porphyria: studies of the severe homozygous dominant disease provides insights into the neurologic attacks in acute porphyrias.
    Solis C; Martinez-Bermejo A; Naidich TP; Kaufmann WE; Astrin KH; Bishop DF; Desnick RJ
    Arch Neurol; 2004 Nov; 61(11):1764-70. PubMed ID: 15534187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute intermittent porphyria: characterization of two novel mutations in the porphobilinogen deaminase gene, one amino acid deletion (453-455delAGC) and one splicing aceptor site mutation (IVS8-1G>T).
    De Siervi A; Mendez M; Parera VE; Varela L; Batlle AM; Rossetti MV
    Hum Mutat; 1999 Oct; 14(4):355. PubMed ID: 10502788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute intermittent porphyria: laboratory diagnosis by molecular methods.
    Schreiber WE
    Clin Lab Med; 1995 Dec; 15(4):943-56. PubMed ID: 8838232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and characterization of hydroxymethylbilane synthase mutations causing acute intermittent porphyria: evidence for an ancestral founder of the common G111R mutation.
    De Siervi A; Rossetti MV; Parera VE; Astrin KH; Aizencang GI; Glass IA; Batlle AM; Desnick RJ
    Am J Med Genet; 1999 Oct; 86(4):366-75. PubMed ID: 10494093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two different point G to A mutations in exon 10 of the porphobilinogen deaminase gene are responsible for acute intermittent porphyria.
    Delfau MH; Picat C; de Rooij FW; Hamer K; Bogard M; Wilson JH; Deybach JC; Nordmann Y; Grandchamp B
    J Clin Invest; 1990 Nov; 86(5):1511-6. PubMed ID: 2243128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of two isoalleles and three mutations in both isoforms of purified recombinant human porphobilinogen deaminase.
    Brøns-Poulsen J; Christiansen L; Petersen NE; Hørder M; Kristiansen K
    Scand J Clin Lab Invest; 2005; 65(2):93-105. PubMed ID: 16025832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion.
    Sardh E; Rejkjaer L; Andersson DE; Harper P
    Clin Pharmacokinet; 2007; 46(4):335-49. PubMed ID: 17375984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Three new mutations in the porphobilinogen deaminase gene, detected in acute intermittent porphyria patients from Russia].
    Surin VL; Luk'ianenko AV; Karpova IV; Misiurin AV; Pustovot IaS; Pivnik AV
    Genetika; 2001 May; 37(5):690-7. PubMed ID: 11436563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The W198X and R173W mutations in the porphobilinogen deaminase gene in acute intermittent porphyria have higher clinical penetrance than R167W. A population-based study.
    Andersson C; Floderus Y; Wikberg A; Lithner F
    Scand J Clin Lab Invest; 2000 Nov; 60(7):643-8. PubMed ID: 11202057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France.
    Nordmann Y; Puy H; Da Silva V; Simonin S; Robreau AM; Bonaiti C; Phung LN; Deybach JC
    J Intern Med; 1997 Sep; 242(3):213-7. PubMed ID: 9350165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute intermittent porphyria: characterization of a novel mutation in the structural gene for porphobilinogen deaminase. Demonstration of noncatalytic enzyme intermediates stabilized by bound substrate.
    Desnick RJ; Ostasiewicz LT; Tishler PA; Mustajoki P
    J Clin Invest; 1985 Aug; 76(2):865-74. PubMed ID: 3897290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of two novel mutations that produce acute intermittent porphyria: A 3-base deletion (841-843delGGA) and a missense mutation (T35M).
    De Siervi A; Weiss Cádiz DE; Parera VE; del C Batlle AM; Rossetti MV
    Hum Mutat; 2000 Oct; 16(4):373. PubMed ID: 11013452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.